Sompraz%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520hp

# Sompraz ## Overview Sompraz is a brand name for pantoprazole, a proton pump inhibitor (PPI). It works by reducing the amount of acid produced in the stomach. ## Primary Indications * Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD) * Maintenance of healing of erosive esophagitis * Symptomatic GERD * Part of a treatment regimen for *Helicobacter pylori* infection (in combination with antibiotics) ## Adult Dosing * **Erosive Esophagitis (Healing):** 40 mg orally once daily for up to 8 weeks. * **Erosive Esophagitis (Maintenance):** 40 mg orally once daily. * **Symptomatic GERD:** 20 mg orally once daily for up to 4 weeks. If symptoms do not resolve, consider further evaluation. * ***H. pylori* Eradication:** 40 mg orally twice daily for 7 days in combination with specific antibiotics (e.g., amoxicillin and clarithromycin, or clarithromycin and metronidazole). ## Pediatric Dosing * **Erosive Esophagitis (ages 5-16 years):** 20 mg or 40 mg orally once daily, depending on severity, for up to 8 weeks. * **Symptomatic GERD (ages 5-16 years):** 20 mg orally once daily for up to 4 weeks. *Note: Dosing in pediatric patients may be based on local protocols and clinical judgment.* ## Dose Adjustments * No dose adjustment is typically required for patients with hepatic impairment. However, caution and dose reduction to 20 mg daily may be considered in severe hepatic impairment. * No dose adjustment is typically required for patients with renal impairment. ## Contraindications * Known hypersensitivity to pantoprazole, any component of the formulation, or any other substituted benzimidazole. ## Adverse Effects Common adverse effects include headache, diarrhea, nausea, abdominal pain, dizziness, and flatulence. Long-term use of PPIs may be associated with an increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), vitamin B12 deficiency, and hypomagnesemia. ## Key Drug Interactions * **Antiretrovirals:** Pantoprazole may decrease the absorption of certain antiretroviral drugs (e.g., atazanavir, nelfinavir). * **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. * **CYP2C19 Substrates:** Pantoprazole can inhibit CYP2C19, potentially affecting the metabolism of drugs like clopidogrel, citalopram, and diazepam. ## Monitoring * Monitor for signs and symptoms of *Clostridium difficile*-associated diarrhea. * Assess for clinical improvement of GERD symptoms. * Consider monitoring serum magnesium levels, especially with prolonged use (e.g., >1 year) or concurrent use of diuretics or digoxin. * Monitor bone mineral density in patients at risk for osteoporosis. ## Clinical Pearls * Administer pantoprazole delayed-release tablets 30 minutes before a meal. * Do not crush or chew delayed-release tablets. * Long-term use should be re-evaluated periodically, especially for indications like GERD. *** **Disclaimer:** This information is intended for clinical use and does not replace the official prescribing information. Always consult the most current drug monograph or product labeling for complete information before making treatment decisions.